Literature DB >> 19696226

Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.

Robert W Schrier1.   

Abstract

The relationship between renal volume and hypertension in autosomal dominant polycystic kidney disease (ADPKD) occurs in childhood. Hypertension is associated not only with increased kidney volume but also with significantly increased left ventricular mass index. Moreover, this increase in left ventricular mass index occurs in children who have ADPKD with borderline hypertension (75th to 95th percentile) and is prevented with angiotensin-converting enzyme inhibitor (ACEI) monotherapy. Progression from borderline to overt hypertension (> or =95th percentile) occurs during a 5-yr follow-up in approximately 50% of children with ADPKD and borderline hypertension. Renal cyst enlargement in ADPKD in adults is associated with stimulation of both the circulating and intrarenal renin-angiotensin-aldosterone system. In addition to hypertension, the resultant angiotensin in ADPKD is a pivotal factor in cyst proliferation and expansion, increased sympathetic and endothelin activity, oxidant injury, and fibrosis. There is a close correlation between the level of hypertension, left ventricular hypertrophy, deterioration of GFR, and the progressive enlargement of the cystic kidneys in adult ADPKD. Randomized clinical investigation indicates that ACEI and a BP goal of 120/80 mmHg are associated in a 7-yr study to reverse left ventricular hypertrophy. The effect of renin-angiotensin-aldosterone system inhibition with dual blockade, ACEI and angiotensin receptor antagonists, on renal volume and kidney function is under study in the Halt Progression of Polycystic Kidney Disease (HALT PKD) trial.

Entities:  

Mesh:

Year:  2009        PMID: 19696226     DOI: 10.1681/ASN.2008080882

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  51 in total

1.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Kaleab Z Abebe; Arlene B Chapman; Robert W Schrier; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Charity G Moore; Ronald D Perrone
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

Review 3.  Autosomal dominant polycystic kidney disease in children.

Authors:  Melissa A Cadnapaphornchai
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

4.  Tissue-engineered three-dimensional in vitro models for normal and diseased kidney.

Authors:  Balajikarthick Subramanian; Darya Rudym; Chris Cannizzaro; Ronald Perrone; Jing Zhou; David L Kaplan
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

5.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

6.  Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms.

Authors:  Djalila Mekahli; Adrian S Woolf; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2010-08-05       Impact factor: 3.714

Review 7.  Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

Authors:  Imed Helal; Godela M Fick-Brosnahan; Berenice Reed-Gitomer; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

8.  Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Authors:  Vicente E Torres; Arlene B Chapman; Ronald D Perrone; K Ty Bae; Kaleab Z Abebe; James E Bost; Dana C Miskulin; Theodore I Steinman; William E Braun; Franz T Winklhofer; Marie C Hogan; Frederic R Oskoui; Cass Kelleher; Amirali Masoumi; James Glockner; Neil J Halin; Diego R Martin; Erick Remer; Nayana Patel; Ivan Pedrosa; Louis H Wetzel; Paul A Thompson; J Philip Miller; Catherine M Meyers; Robert W Schrier
Journal:  Kidney Int       Date:  2011-12-28       Impact factor: 10.612

9.  Decade in review--polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2015-10-13       Impact factor: 28.314

10.  The HALT polycystic kidney disease trials: design and implementation.

Authors:  Arlene B Chapman; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Kyongtae T Bae; J Philip Miller; Dana C Miskulin; Frederic Rahbari Oskoui; Amirali Masoumi; Marie C Hogan; Franz T Winklhofer; William Braun; Paul A Thompson; Catherine M Meyers; Cass Kelleher; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2010-01       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.